Orphanet: Recherche simple

Rechercher un essai clinique

Autre(s) option(s) de recherche

95 Résultat(s)

Essai(s) clinique(s) national(aux)

A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma - US Perelman Center for Advanced Medicine

Etude de Phase I multicentrique en ouvert évaluant IPH4102, un anticorps humanisé anti-KIR3DL2, chez des patients atteints de lymphomes cutanés à cellules T (LCCT) en rechutes ou réfractaires - FR GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis Service de dermatologie

A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma Policlinico S. Orsola-Malpighi - Area S. Orsola Dipartimento di Ematologia e Scienze Oncologiche

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment. Centrum Onkologii im. prof. F. Lukaszczyka

CHEMO-T: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II study - UK University of Cambridge Department of Medicine

ALL-REZ BFM 2002: Multicentre Study for Children With Relapsed Acute Lymphoblastic Leukemia Otto-Heubner-Centrum für Kinder- und Jugendmedizin Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Deutsches Krebsforschungszentrum Klinische Kooperationseinheit Pädiatrische Onkologie

CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma Zentrum für Innere Medizin (Krehl-Klinik) Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Phase IIA Study on Therapy in Patients With Cutaneous T Cell Lymphoma - DE Universitätsmedizin Mannheim Klinik für Dermatologie, Venerologie und Allergologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Regensburg Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universitätsklinikum Würzburg

PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE Institution: Information not provided - DE

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Charité - Universitätsmedizin Berlin

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Essen Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universitätsklinikum Münster

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universität Leipzig

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT Universitätsklinikum der Paracelsus Medizinischen Privatuniversität Universitätsklinik für Innere Medizin III

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT Medizinische Universität Innsbruck Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas - AT Institution: Information not provided - AT

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT Institution: Information not provided - AT

PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome (Phase 2) - AT Institution: Information not provided - AT

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA British Columbia Cancer Agency

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA Sunnybrook Health Sciences Centre Sunnybrook Research Institute

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA The Research Institute of the McGill University Health Centre

CheckMate 436: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - ES ICO Hospitalet - Hospital Duran i Reynals Servicio de Hematología Clínica

CHRONOS-1: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas - ES Hospital Universitario y Politécnico La Fe Servicio de Oncología Médica

UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES Institution: Information not provided - ES

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma - ES Institution: Information not provided - ES

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - ES Institution: Information not provided - ES

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES Institution: Information not provided - ES

MOGAT: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma - ES Institution: Information not provided - ES

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - ES Institution: Information not provided - ES

An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma - FR Institution: Information not provided - FR

Etude de phase III multicentrique randomisée pour comparer l'efficacité et la tolérance de l'association romidepsine CHOP (Ro-CHOP) versus CHOP chez des patients atteints d'un lymphome T périphérique non préalablement traité - FR CHU de Lyon HCL - GH Sud Service d'hématologie clinique

AcSé : Accès sécurisé au Pembrolizumab pour des patients adultes porteurs de certains types de cancers rares (Phase II) CLCC Institut Gustave Roussy Département d'Innovation Thérapeutique et d'Essais Précoces

Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques CLCC Institut Gustave Roussy Département d'hématologie

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - FR CHU de Nantes - Hôtel Dieu Service d'hématologie clinique

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR CLCC Institut Paoli Calmettes Institut Paoli-Calmettes

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IL Institution: Information not provided - IL

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders Institution: Information not provided - IT

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IT ASST Grande Ospedale Metropolitano Niguarda S.C di Ematologia

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study Fondazione IRCCS Istituto Nazionale dei Tumori Dipartimento di Ematologia e Trapianto Osseo Allogenico

A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy IRCCS Istituto Clinico Humanitas U.O. Oncologia Medica ed Ematologia

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette S.C. di Ematologia

COMPARE 60/80 HBR: Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population Maasstad Ziekenhuis Polikliniek Cardiologie

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - PL Institution: Information not provided - PL

UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB Addenbrooke's Hospital Cambridge Cancer Trials Centre

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB GOSH NHS Foundatin Trust Great Ormond Street Hospital

UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies Guy's Hospital Department of Haematology

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies GlaxoSmithKline

AVAIL-T: A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma Institution: Information not provided - UK

NCRN2401 - An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma (Phase II) - UK The Christie, NHS Foundation Trust Department of Medical Oncology

RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma Churchill Hospital Department of Haematology

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma-GB University of Birmingham University of Birmingham HQ

Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study Inselspital Universitätsspital Universitätsklinik für Medizinische Onkologie

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH Ospedale Regionale di Bellinzona e Valli

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CZ Institution: Information not provided - CZ

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype - AT Institution: Information not provided - AT

STEP: Programme d'extension à long terme du Sorafénib - BE Cliniques universitaires Saint-Luc - UCLouvain Pneumologie_Oncologie thoracique

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO U.O. di Oncoematologia

Essai(s) clinique(s) multinational(aux)

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (PhaseI) (coordination) Merck KGaA

PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome EORTC European Organisation for the Research and Treatment of Cancer

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment EORTC European Organisation for the Research and Treatment of Cancer

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) (Coordination) Hospital Clínico Universitario de Salamanca Servicio de Hematología

A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination) PharmaMar S.A. Pharma Mar S.A.

A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Children's Hospital Los Angeles Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL) Celgene Corporation

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders Bellicum Pharmaceuticals, Inc.

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Institution: Information not provided - US

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma Innate Pharma SA

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination) Hoffmann-La Roche Hoffmann - La Roche Ltd.

PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study (Phase II) miRagen Therapeutics, Inc.

APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination) PharmaMar S.A. Pharma Mar S.A.

A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma - US
Perelman Center for Advanced Medicine

Etude de Phase I multicentrique en ouvert évaluant IPH4102, un anticorps humanisé anti-KIR3DL2, chez des patients atteints de lymphomes cutanés à cellules T (LCCT) en rechutes ou réfractaires - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis

Service de dermatologie

A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma
Policlinico S. Orsola-Malpighi - Area S. Orsola

Dipartimento di Ematologia e Scienze Oncologiche

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.
Centrum Onkologii im. prof. F. Lukaszczyka

CHEMO-T: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II study - UK
University of Cambridge

Department of Medicine

ALL-REZ BFM 2002: Multicentre Study for Children With Relapsed Acute Lymphoblastic Leukemia
Otto-Heubner-Centrum für Kinder- und Jugendmedizin

Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum

Klinische Kooperationseinheit Pädiatrische Onkologie

CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
Zentrum für Innere Medizin (Krehl-Klinik)

Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Phase IIA Study on Therapy in Patients With Cutaneous T Cell Lymphoma - DE
Universitätsmedizin Mannheim

Klinik für Dermatologie, Venerologie und Allergologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg

Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg

PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen

Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universität Leipzig

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

Universitätsklinik für Innere Medizin III

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Medizinische Universität Innsbruck

Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas - AT
Institution: Information not provided - AT

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT

PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome (Phase 2) - AT
Institution: Information not provided - AT

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
British Columbia Cancer Agency

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
Sunnybrook Health Sciences Centre

Sunnybrook Research Institute

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
The Research Institute of the McGill University Health Centre

CheckMate 436: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - ES
ICO Hospitalet - Hospital Duran i Reynals

Servicio de Hematología Clínica

CHRONOS-1: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas - ES
Hospital Universitario y Politécnico La Fe

Servicio de Oncología Médica

UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES
Institution: Information not provided - ES

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma - ES
Institution: Information not provided - ES

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - ES
Institution: Information not provided - ES

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES
Institution: Information not provided - ES

MOGAT: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma - ES
Institution: Information not provided - ES

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - ES
Institution: Information not provided - ES

An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma - FR
Institution: Information not provided - FR

Etude de phase III multicentrique randomisée pour comparer l'efficacité et la tolérance de l'association romidepsine CHOP (Ro-CHOP) versus CHOP chez des patients atteints d'un lymphome T périphérique non préalablement traité - FR
CHU de Lyon HCL - GH Sud

Service d'hématologie clinique

AcSé : Accès sécurisé au Pembrolizumab pour des patients adultes porteurs de certains types de cancers rares (Phase II)
CLCC Institut Gustave Roussy

Département d'Innovation Thérapeutique et d'Essais Précoces

Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques
CLCC Institut Gustave Roussy

Département d'hématologie

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - FR
CHU de Nantes - Hôtel Dieu

Service d'hématologie clinique

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes

Institut Paoli-Calmettes

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IL
Institution: Information not provided - IL

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IT
ASST Grande Ospedale Metropolitano Niguarda

S.C di Ematologia

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Fondazione IRCCS Istituto Nazionale dei Tumori

Dipartimento di Ematologia e Trapianto Osseo Allogenico

A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy
IRCCS Istituto Clinico Humanitas

U.O. Oncologia Medica ed Ematologia

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette

S.C. di Ematologia

COMPARE 60/80 HBR: Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Maasstad Ziekenhuis

Polikliniek Cardiologie

ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - PL
Institution: Information not provided - PL

UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital

Cambridge Cancer Trials Centre

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust

Great Ormond Street Hospital

UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital

Department of Haematology

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies
GlaxoSmithKline

AVAIL-T: A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - UK

NCRN2401 - An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma (Phase II) - UK
The Christie, NHS Foundation Trust

Department of Medical Oncology

RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Churchill Hospital

Department of Haematology

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma-GB
University of Birmingham

University of Birmingham HQ

Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Inselspital Universitätsspital

Universitätsklinik für Medizinische Onkologie

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli

ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CZ
Institution: Information not provided - CZ

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype - AT
Institution: Information not provided - AT

STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain

Pneumologie_Oncologie thoracique

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO

U.O. di Oncoematologia

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (PhaseI) (coordination)
Merck KGaA

PROMPT: A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic Mycosis Fungoides and Sezary Syndrome
EORTC

European Organisation for the Research and Treatment of Cancer

PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment
EORTC

European Organisation for the Research and Treatment of Cancer

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) (Coordination)
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination)
PharmaMar S.A.

Pharma Mar S.A.

A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles

Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL)
Celgene Corporation

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma
Innate Pharma SA

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche

Hoffmann - La Roche Ltd.

PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study (Phase II)
miRagen Therapeutics, Inc.

APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)
PharmaMar S.A.

Pharma Mar S.A.